Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
113
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.50 | 39.20 | 0.44% |
| CAC 40 | 7,808.17 | 21.12 | -0.27% |
| DAX 40 | 24,160.64 | 94.67 | -0.39% |
| Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
| FTSE 100 | 8,998.06 | 56.94 | 0.64% |
| HKSE | 24,479.98 | 276.66 | 1.14% |
| NASDAQ | 20,640.33 | 54.80 | 0.27% |
| Nikkei 225 | 39,570.24 | 110.62 | 0.28% |
| NZX 50 Index | 12,679.36 | 0.67 | 0.01% |
| S&P 500 | 6,268.56 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,610.70 | 40.30 | 0.47% |
| SSE Composite Index | 3,523.27 | 3.62 | 0.10% |